{"title":"佩罗尼氏病:综述和最新治疗进展。","authors":"Jacqueline Pires, Michelle Travis, Pamela Ellsworth","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Peyronie's disease is a chronic condition affecting approximately 3% to 9% of adult males and is associated with significant negative effects on physical and psychosocial well-being and quality of life. Historically, treatment has been limited by a lack of understanding of the pathophysiology. Recent advances have led to the first FDA-approved therapy for the treatment of Peyronie's disease. Evaluation, treatment, and management of patients with this condition, including use of an algorithm and pre-/post-treatment questionnaire, will be discussed.</p>","PeriodicalId":23510,"journal":{"name":"Urologic nursing","volume":"35 4","pages":"164-78"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peyronie's Disease: Overview and Recent Treatment Advances.\",\"authors\":\"Jacqueline Pires, Michelle Travis, Pamela Ellsworth\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Peyronie's disease is a chronic condition affecting approximately 3% to 9% of adult males and is associated with significant negative effects on physical and psychosocial well-being and quality of life. Historically, treatment has been limited by a lack of understanding of the pathophysiology. Recent advances have led to the first FDA-approved therapy for the treatment of Peyronie's disease. Evaluation, treatment, and management of patients with this condition, including use of an algorithm and pre-/post-treatment questionnaire, will be discussed.</p>\",\"PeriodicalId\":23510,\"journal\":{\"name\":\"Urologic nursing\",\"volume\":\"35 4\",\"pages\":\"164-78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic nursing","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Peyronie's Disease: Overview and Recent Treatment Advances.
Peyronie's disease is a chronic condition affecting approximately 3% to 9% of adult males and is associated with significant negative effects on physical and psychosocial well-being and quality of life. Historically, treatment has been limited by a lack of understanding of the pathophysiology. Recent advances have led to the first FDA-approved therapy for the treatment of Peyronie's disease. Evaluation, treatment, and management of patients with this condition, including use of an algorithm and pre-/post-treatment questionnaire, will be discussed.